LFMD
LifeMD, Inc. (LFMD)
Healthcare • Health Information Services • $4.15 • MCap: 200,704,432
🌐
https://lifemd.com • LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men's telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men's health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss. The company also provides LifeMD PC, a virtual primary care and telehealth service which is a provider for their primary care, urgent care, and chronic care needs; and offers virtual medical care, including on-demand consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, integration with in-home tools, and more. In addition, it offers GLP-1 for weight management and in-home health monitoring devices. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.
Buy Decision Core
Total Score
35
Business Quality
10
Financial Strength
4
Growth Outlook
1
Momentum
3
Price Action
Current
4.15
52W High
12.35
52W Low
2.64
Above 50DMA
4.57 (-9.17%)
Above 200DMA
4.29 (-3.23%)
Relative Strength
Relative Strength
-0.15
RS 3M
0.05
RS 6M
0.08
RS 9M
-0.35
RS 12M
-0.6
Fundamentals
Revenue Growth
-0.01%
Earnings Growth
0%
ROE
-2.38%
ROA
-0.13%
Valuation
PE (Fwd)
8.06
PEG
0
P/B
13.13
Upside
137.95%
Risk
Beta
1.99
Short %
0.16
Risk Score
8.00
Analyst
Rating
strong_buy
Target
9.88
Beta
1.99
Analysts
0
Total Score
35
Upside
137.95%
Relative Strength
-0.15
Beta
1.99
Why Buy?
- PEG Ratio below 1 (attractive valuation)
- Analyst upside exceeds 15%
Key Risks
- Revenue growth is negative
- Negative ROE
- High volatility (Beta > 1.5)
- Weak long-term relative strength
Score Breakdown
Business
10
10
Financial
4
4
Growth
1
1
Valuation
13
13
Risk
0
0
Momentum
3
3
Technical
52W High: 12.35
52W Low: 2.64
Above 50DMA: -9.17%
Above 200DMA: -3.23%
Valuation
Forward PE: 8.06
PEG: 0
P/B: 13.13
Upside: 137.95%
Risk
Beta: 1.99
Short Float: 0.16%
ROE: -2.38%
ROA: -0.13%